ProShare Advisors
KLDO

ProShare Advisors’s Kaleido Biosciences, Inc. Common Stock KLDO Stock Holding History

ProShare Advisors’s Portfolio KLDO Stock Details KLDO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q4 		– Sell
-11,578
Closed -$63K – 2359
2021
Q3 		$63K Sell
11,578
-1,087
-9% -$6.74K ﹤0.01% 1955
2021
Q2 		$94K Buy
+12,665
New +$89.8K ﹤0.01% 2303

Other funds holding KLDO

FP
Flagship Pioneering Cambridge, Massachusetts $1.16B AUM 67.93% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
HP
Harbourvest Partners Boston, Massachusetts $101M AUM 38.13% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return
AG
Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
PAI
Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return

ProShare Advisors's KLDO Position: Q4 2021 in Review

ProShare Advisors sold out of Kaleido Biosciences, Inc. Common Stock (KLDO) in Q4 2021, closing a stake of 11,578 shares — an estimated $63K sold.

ProShare Advisors first reported a position in KLDO in Q2 2021 and held it in 2 quarters. The position peaked at $94K in Q2 2021. 66 funds tracked by Wall St. Rank hold KLDO as of Q4 2021.

  • ProShare Advisors reported no remaining Kaleido Biosciences, Inc. Common Stock position as of Q4 2021 after selling out during the quarter.
  • ProShare Advisors sold 11,578 Kaleido Biosciences, Inc. Common Stock shares in Q4 2021, an estimated $63K.
  • ProShare Advisors first reported a position in Kaleido Biosciences, Inc. Common Stock in Q2 2021 and held it in 2 quarters.
  • ProShare Advisors's Kaleido Biosciences, Inc. Common Stock position peaked at $94K in Q2 2021.
  • 66 funds tracked by Wall St. Rank held Kaleido Biosciences, Inc. Common Stock as of Q4 2021.

Based on ProShare Advisors's 13F filing for Q4 2021, filed 8 Feb 2022.